Floatz logo

Donanemab

Plaque, Amyloid

Eli Lilly and Companymonoclonal_antibodyPhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Plaque, Amyloid cohort.

Asset / SponsorPhaseRating
cc-5013
St. Joseph's Hospital and Medical Center, Phoenix
Phase 2B
Aci-24.060
AC Immune SA
Phase 1/2CCC

Same molecule, other indications

Donanemab is also rated in:

Alzheimer diseaseDormant
BB
Indicative ·
70 / 100
View asset →
Down syndromeDormant
BB
Indicative ·
65 / 100
View asset →
APP-related brain and vascular amyloidosisDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →